Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
Abstract Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Therefore, in this study, the PKs of remdesivir and its major...
保存先:
主要な著者: | , , , , , , , , , |
---|---|
フォーマット: | 図書 |
出版事項: |
Wiley,
2023-04-01T00:00:00Z.
|
主題: | |
オンライン・アクセス: | Connect to this object online. |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
請求記号: |
A1234.567 |
---|---|
所蔵 1 | 利用可 |